Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized post-myocardial infarction medical therapy to prevent heart failure
ACTRN12610000802000Phase 4Not yet recruiting
- Sponsor
- Pahr Therapeutics
- Start
- Nov 2010
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carvedilol, bisoprolol, metoprolol, nebivolol, ramipril and 6 more in heart failure (HF) (2 arms), sponsored by Pahr Therapeutics. Primary endpoint: New heart failure hospitalisation. Planned start Nov 2010; status: not yet recruiting.
02
Drugs
carvedilolbisoprololmetoprololnebivololramipril
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ACTRN12610000802000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000802000.